-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Upgrades Tvardi Therapeutics to Outperform, Announces $10 Price Target

Benzinga·07/08/2026 10:02:13
Listen to the news
Raymond James analyst Ryan Deschner upgrades Tvardi Therapeutics (NASDAQ:TVRD) from Market Perform to Outperform and announces $10 price target.